Compare ABSI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABSI | ESPR |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.9M | 731.9M |
| IPO Year | 2021 | 2013 |
| Metric | ABSI | ESPR |
|---|---|---|
| Price | $3.04 | $2.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.47 | ★ $7.60 |
| AVG Volume (30 Days) | 4.0M | ★ 5.2M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.64 | ★ 60.71 |
| EPS | N/A | ★ N/A |
| Revenue | $4,534,000.00 | ★ $403,135,000.00 |
| Revenue This Year | $631.04 | $2.92 |
| Revenue Next Year | $75.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $2.01 | $0.73 |
| 52 Week High | $5.23 | $4.18 |
| Indicator | ABSI | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 43.81 |
| Support Level | $2.45 | $2.37 |
| Resistance Level | $3.26 | $3.02 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 74.43 | 47.02 |
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.